BetaShares Geared Australian Equity Fund logo

BetaShares Geared Australian Equity Fund (GEAR)

Market Closed
ASX ASX
- Market Cap
- Div Yield
106,470 Volume
Want to track GEAR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

GEAR pays dividends to its shareholders, with the most recent payment made on Jul 16, 2026. The next estimated payment will be in In 5 months on Jan 16, 2027 for a total of A$0.20484.
The stock of the company had never split.
The company's stock is traded on one exchange.

BetaShares Geared Australian Equity Fund (GEAR) FAQ

On which exchange is it traded?

BetaShares Geared Australian Equity Fund is listed on ASX.

What is its stock symbol?

The ticker symbol is GEAR.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has BetaShares Geared Australian Equity Fund ever had a stock split?

No, there has never been a stock split.

BetaShares Geared Australian Equity Fund Profile

ASX Exchange
CN Country

Overview

Shanghai Junshi Biosciences Co., Ltd. is a prominent biopharmaceutical company founded in 2012 and is located in Shanghai, People's Republic of China. This enterprise is specialized in the discovery, development, and commercialization of a wide range of drugs aimed at treating various medical conditions including oncology, metabolic disorders, autoimmune diseases, neurologic and nervous system issues, as well as infectious diseases. With its focus on innovation and using cutting-edge technology, Shanghai Junshi Biosciences is dedicated to advancing healthcare and improving the quality of life for patients across the People's Republic of China.

Products and Services

Shanghai Junshi Biosciences Co., Ltd. offers an extensive portfolio of drugs and therapies in various stages of development and commercialization. Their products and services are primarily aimed at addressing the unmet medical needs in the following therapeutic areas:

  • Oncology: Developing novel treatments for various types of cancer, Junshi Biosciences aims to improve survival rates and the quality of life for cancer patients. Their oncology portfolio includes drugs that target specific pathways and mechanisms involved in cancer growth and progression.
  • Metabolic Diseases: The company is involved in creating therapeutic solutions for metabolic disorders such as diabetes and obesity. These treatments focus on regulating metabolism and providing better disease management for affected individuals.
  • Autoimmune Diseases: Immunotherapy drugs developed by Junshi Biosciences seek to modulate the immune system to treat autoimmune diseases, helping to reduce inflammation and autoimmune responses that characterize conditions such as rheumatoid arthritis and lupus.
  • Neurologic and Nervous System Disorders: The company is also focusing on drugs that address diseases of the central and peripheral nervous systems, including neurodegenerative diseases and neuropathic pain, aiming to enhance the quality of life for people suffering from these conditions.
  • Infectious Diseases: Junshi Biosciences develops antiviral and antibiotic drugs to combat infectious diseases, contributing to the global fight against emerging and re-emerging infectious threats.

Contact Information

Address: Building 7
Phone: 86 21 6105 8800